{"id":"NCT01500694","sponsor":"Shire","briefTitle":"Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe","officialTitle":"A Phase 3, Open-label, Multicentre Study to Provide Access to Guanfacine Hydrochloride Extended-release for European Subjects With Attention-deficit/Hyperactivity Disorder (ADHD) Who Participated in Study SPD503-315 or SPD503-316","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03-20","primaryCompletion":"2015-09-15","completion":"2015-09-15","firstPosted":"2011-12-28","resultsPosted":"2017-05-18","lastUpdate":"2021-06-16"},"enrollment":215,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder (ADHD)"],"interventions":[{"type":"DRUG","name":"Extended-release Guanfacine HCl (Intuniv, SPD503)","otherNames":["Intuniv","SPD503"]}],"arms":[{"label":"Extended-release Guanfacine HCl","type":"EXPERIMENTAL"}],"summary":"For subjects in Europe that have already participated in either Study SPD503-315 or SPD503-316. This is an extension study that will allow participants access to Extended-release Guanfacine Hydrochloride (HCl) for up to 2 years. This study will help the sponsor evaluate long-term safety and tolerability of Extended-release Guanfacine HCl (SPD503).","primaryOutcome":{"measure":"Change From Baseline in Mean Systolic Blood Pressure at Final Assessment","timeFrame":"Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)","effectByArm":[{"arm":"SPD503 (6-12 Years)","deltaMin":107.5,"sd":8.73},{"arm":"SPD503 (13-18 Years)","deltaMin":113.5,"sd":9.23}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":60,"countries":["Austria","Belgium","France","Germany","Ireland","Italy","Netherlands","Poland","Romania","Spain","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":["29442229"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":131},"commonTop":["Somnolence","Headache","Fatigue","Nasopharyngitis","Dizziness"]}}